M&A
confidence high
sentiment positive
materiality 0.85
Zymeworks licenses DLL3 T-cell engager ZW209 to Roche for $55M upfront, up to $758M in milestones
Zymeworks Inc.
- Roche pays $55M upfront after HSR clearance, plus a $40M milestone on the first ZW209 Phase 1b trial; up to $718M in development, commercial and sales milestones.
- Zymeworks also gets tiered high-single-digit to mid-teen royalties on global net sales, payable until the later of 10 years post-launch or patent expiry (patents into the 2040s).
- Zymeworks runs the Phase 1a monotherapy trial at Roche's expense; Roche funds it and takes over all later global development, manufacturing and commercialization.
- Exclusive worldwide license covers ZW209 and other DLL3 trispecific T-cell engagers; Zymeworks is barred from DLL3 T-cell engager work for up to 5 years or first Phase 3 start.
- FDA IND clearance for ZW209 received; deal still subject to HSR waiting period; investor call October 27 at 8:30 am ET.